Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $48.4250 (-3.52%) ($48.4250 - $48.4250) on Tue. Mar. 23, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.35% (three month average) | RSI | 64 | Latest Price | $48.4250(-3.52%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.6% a day on average for past five trading days. | Weekly Trend | TGTX advances 5.6% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(63%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.675% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-18%) UNG(-3%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.675% (StdDev 3.35%) | Hourly BBV | -0.8 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $48.39(0.07%) | 10 Day Moving Average | $48.39(0.07%) | 20 Day Moving Average | $46.16(4.91%) | To recent high | -10.7% | To recent low | 16.2% | Market Cap | $6.133b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |